ASCO GU 2018: Effects Of a 6-month Moderate-intensity Exercise Program on Metabolic Parameters and Bone Mineral Density in Men on Androgen Deprivation Therapy for Prostate Cancer.
San Francisco, CA (UroToday.com) Androgen deprivation therapy (ADT) is commonly used to treat prostate cancer (PC) but is associated with significant side effects including metabolic abnormalities and bone loss. Although multiple trials have demonstrated that exercise is associated with improvements in associated multiple side effects caused by ADT, its effects on metabolic and skeletal outcomes is unclear.
ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM.
San Francisco, CA (UroToday.com) Germline mutations in homologous recombination repair (HRR) genes, including BRCA2, are prevalent in 6-12% of pts with metastatic castration-resistant prostate cancer (mCRPC). BRCA2 germline mutations are associated with high-grade, early onset, and poor-prognosis localized disease, while outcomes in pts with advanced prostate cancer continue to be defined.
ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality
San Francisco, CA (UroToday.com) Dr. Kim Chi gave an excellent talk on the incorporation of genomics into the management of systemic therapy. Dr. Chi began his presentation with stating some key points. Genomic profiling of castrate resistant prostate cancer (CRPC) tissues reveals driver aberrations that are clinically relevant. Circulating tumor DNA (ct DNA) is an effective tool to identify mutations and copy number changes in men with CRPC. Deleterious genomic alterations have been associated with treatment outcomes and have the potential to inform patient management. The challenge is to find the next best treatment for patients entering the CRPC state.
ASCO GU 2018: Impact of Sexual Orientation on Contemporary Rates of Prostate Cancer Screening
San Francisco, CA (UroToday.com) Dr. Daniel Pucheril and colleagues presented their findings regarding the impact of sexual orientation on contemporary rates of prostate cancer screening. Although there has been increasing societal acceptance of non-heterosexual individuals, sexual minorities continue to face discrimination. The effect of non-heterosexual orientation on adoption of cancer preventive services, specifically prostate cancer screening, is essentially unknown.
ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis
San Francisco, CA (UroToday.com) Dr. Ramsankar Basak presented on the assessment he and his colleagues performed in which they utilized a population-level analysis to assess why men with low-risk prostate cancer are treated aggressively. As per the AUA guidelines , active surveillance is the best option for men with very low-risk prostate cancer and preferred option for all low-risk patients. However, despite improved adoption, active surveillance continues to be underused.
ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone
San Francisco, CA (UroToday.com) Epidemiologic studies have demonstrated an association between statin use and improved prostate cancer specific mortality. Several different biologic mechanisms for such an effect have been proposed, including a potential role in reducing androgen precursor bioavailability. The authors have hypothesized that statins may therefore improve outcomes specifically in patients treated with the CYP17 inhibitor Abiraterone (ABI). Di Lorenzo (2017) recently published an analysis of 187 pts showing a relationship between ABI and improved survival (OS).
ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer
San Francisco, CA (UroToday.com) Dr. Albert Kim and colleagues from Cleveland, OH presented results of their national survey of radiation oncologists and urologists on active surveillance for low-risk prostate cancer at today’s prostate cancer poster session at GU ASCO. Secondary to the growing concerns about over-diagnosis and overtreatment of localized prostate cancer, active surveillance has become an integral part of clinical practice guidelines.